D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Snap
SNAP
|
+$436M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$373M |
| 3 |
Fidelity National Information Services
FIS
|
+$351M |
| 4 |
Cisco
CSCO
|
+$350M |
| 5 |
Lockheed Martin
LMT
|
+$348M |
Top Sells
| 1 |
Tesla
TSLA
|
+$771M |
| 2 |
Advanced Micro Devices
AMD
|
+$593M |
| 3 |
Boeing
BA
|
+$590M |
| 4 |
Lowe's Companies
LOW
|
+$519M |
| 5 |
Alibaba
BABA
|
+$352M |
Sector Composition
| 1 | Technology | 19.42% |
| 2 | Consumer Discretionary | 14.02% |
| 3 | Healthcare | 12.06% |
| 4 | Communication Services | 9.1% |
| 5 | Financials | 8.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2326
HCA Healthcare
HCA
$92.3B
| $316K | ﹤0.01% |
1,924
-18,995
| -91% | -$3.12M |
|
2327
Xylem
XYL
$33.5B
| $315K | ﹤0.01% |
3,093
+107
| +4% | +$10.9K |
|
2328
Ericsson
ERIC
$26.5B
| $314K | ﹤0.01% |
26,247
+4,646
| +22% | +$55.6K |
|
|
ADAM
2329
Adamas Trust, Inc. Common Stock
ADAM
$653M
| $314K | ﹤0.01% |
21,275
+15,500
| +268% | +$229K |
|
|
GTHX
2330
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $314K | ﹤0.01% |
+17,465
| New | +$314K |
|
2331
American Vanguard Corp
AVD
$152M
| $313K | ﹤0.01% |
20,194
+8,591
| +74% | +$133K |
|
2332
REX American Resources
REX
$1.01B
| $310K | ﹤0.01% |
12,648
+150
| +1% | +$3.68K |
|
|
FLIC
2333
DELISTED
First of Long Island Corp
FLIC
| $310K | ﹤0.01% |
17,342
-8,395
| -33% | -$150K |
|
2334
Tilly's
TLYS
$60M
| $310K | ﹤0.01% |
37,970
-86,741
| -70% | -$708K |
|
2335
Ichor Holdings
ICHR
$568M
| $305K | ﹤0.01% |
+10,107
| New | +$305K |
|
2336
RBB Bancorp
RBB
$333M
| $302K | ﹤0.01% |
19,650
+5,882
| +43% | +$90.4K |
|
2337
Safe Bulkers
SB
$458M
| $301K | ﹤0.01% |
231,959
+3,493
| +2% | +$4.53K |
|
|
CRHC.WS
2338
DELISTED
Cohn Robbins Holdings Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CRHC.WS
| $300K | ﹤0.01% |
+166,666
| New | +$300K |
|
2339
Fidus Investment
FDUS
$754M
| $299K | ﹤0.01% |
22,813
-32,146
| -58% | -$421K |
|
|
WTRE
2340
DELISTED
Watford Holdings Ltd. Common Shares
WTRE
| $298K | ﹤0.01% |
8,619
-2,409
| -22% | -$83.3K |
|
2341
Pulse Biosciences
PLSE
$994M
| $296K | ﹤0.01% |
+12,391
| New | +$296K |
|
2342
PPG Industries
PPG
$24.6B
| $296K | ﹤0.01% |
2,052
-102,398
| -98% | -$14.8M |
|
2343
Pricesmart
PSMT
$3.41B
| $294K | ﹤0.01% |
3,230
+13
| +0.4% | +$1.18K |
|
|
CLCT
2344
DELISTED
Collectors Universe
CLCT
| $294K | ﹤0.01% |
3,894
-1,100
| -22% | -$83.1K |
|
2345
Insight Enterprises
NSIT
$3.96B
| $292K | ﹤0.01% |
3,837
-28,515
| -88% | -$2.17M |
|
|
ESGR
2346
DELISTED
Enstar Group
ESGR
| $289K | ﹤0.01% |
1,409
+75
| +6% | +$15.4K |
|
2347
Mueller Industries
MLI
$10.8B
| $289K | ﹤0.01% |
16,442
-23,248
| -59% | -$409K |
|
2348
Jabil
JBL
$23.2B
| $288K | ﹤0.01% |
6,779
-29,034
| -81% | -$1.23M |
|
2349
West Pharmaceutical
WST
$18.4B
| $288K | ﹤0.01% |
1,016
-900
| -47% | -$255K |
|
|
NBSE
2350
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $288K | ﹤0.01% |
+2,058
| New | +$288K |
|